Free Trial
NASDAQ:ENSC

Ensysce Biosciences Q2 2025 Earnings Report

Ensysce Biosciences logo
$2.09 +0.01 (+0.48%)
Closing price 04:00 PM Eastern
Extended Trading
$2.10 +0.01 (+0.48%)
As of 05:03 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ensysce Biosciences EPS Results

Actual EPS
N/A
Consensus EPS
-$1.02
Beat/Miss
N/A
One Year Ago EPS
N/A

Ensysce Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
$0.67 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Ensysce Biosciences Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Monday, August 18, 2025
Conference Call Time
4:00PM ET

Conference Call Resources

Ensysce Biosciences Earnings Headlines

Ensysce Biosciences (ENSC) to Release Quarterly Earnings on Wednesday
Elon Musk: “Nothing happens without this…”
Lithium has fueled the EV boom, but another resource is even more critical. Without it, over 20 million electric vehicles could fail to reach production—and the AI revolution could stall. After a year of research, one small-cap stock has emerged as the top contender to benefit from a looming supply crunch.
Ensysce Flat on Receiving Grant
See More Ensysce Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Ensysce Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ensysce Biosciences and other key companies, straight to your email.

About Ensysce Biosciences

Ensysce Biosciences (NASDAQ:ENSC), a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP oxycodone prodrug candidate for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF614, an extended-release oxycodone-derivative that releases clinically effective oxycodone; PF329 for pain with abuse protection; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD; and PF9001 to treat Opioid use disorder. The company was founded in 2003 and is based in La Jolla, California.

View Ensysce Biosciences Profile

More Earnings Resources from MarketBeat